Literature DB >> 34157234

Phosphatidylinositol 3-kinase signaling and immune regulation: insights into disease pathogenesis and clinical implications.

Tina Nguyen1,2, Elissa K Deenick1,2, Stuart G Tangye1,2.   

Abstract

INTRODUCTION: Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase that plays a fundamental role in cell survival, metabolism, proliferation and differentiation. Thus, balanced PI3K signalling is critical for multiple aspects of human health. The discovery that germline variants in genes in the PI3K pathway caused inborn errors of immunity highlighted the non-redundant role of these signalling proteins in the human immune system. The subsequent identification and characterisation of >300 individuals with a novel immune dysregulatory disorder, termed activated PI3K-delta syndrome (APDS), has reinforced the status of PI3K as a key pathway regulating immune function. Studies of APDS have demonstrated that dysregulated PI3K function is disruptive for immune cell development, activation, differentiation, effector function and self-tolerance, which are all important in supporting effective, long-term immune responses. AREAS COVERED: In this review, we recount recent findings regarding humans with germline variants in PI3K genes and discuss the underlying cellular and molecular pathologies, with a focus on implications for therapy in APDS patients. EXPERT OPINION: Modulating PI3K immune cell signalling by offers opportunities for therapeutic interventions in settings of immunodeficiency, autoimmunity and malignancy, but also highlights potential adverse events that may result from overt pharmacological or intrinsic inhibition of PI3K function.

Entities:  

Keywords:  PI3K; autoimmunity; b-cell development; human b cells; immune dysregulation; immunodeficiency; phosphatidylinositol-3-kinase; therapeutics; transitional b cells

Mesh:

Substances:

Year:  2021        PMID: 34157234     DOI: 10.1080/1744666X.2021.1945443

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  3 in total

1.  Dysregulated PI3K Signaling in B Cells of CVID Patients.

Authors:  Ina Harder; Matthias Münchhalfen; Geoffroy Andrieux; Melanie Boerries; Bodo Grimbacher; Hermann Eibel; Maria Elena Maccari; Stephan Ehl; Jürgen Wienands; Julia Jellusova; Klaus Warnatz; Baerbel Keller
Journal:  Cells       Date:  2022-01-28       Impact factor: 6.600

2.  Probiotic Combination CBLEB Alleviates Streptococcus pneumoniae Infection Through Immune Regulation in Immunocompromised Rats.

Authors:  Longxian Lv; Ling Peng; Li Shao; Ding Shi; Huiyong Jiang; Ren Yan
Journal:  J Inflamm Res       Date:  2022-02-15

3.  In-silico molecular modelling, MM/GBSA binding free energy and molecular dynamics simulation study of novel pyrido fused imidazo[4,5-c]quinolines as potential anti-tumor agents.

Authors:  Upala Dasmahapatra; Chitluri Kiran Kumar; Soumyadip Das; Prathima Thimma Subramanian; Poornimaa Murali; Arnold Emerson Isaac; Karuppasamy Ramanathan; Balamurali Mm; Kaushik Chanda
Journal:  Front Chem       Date:  2022-09-30       Impact factor: 5.545

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.